Imagin Medical Inc. (IMEXF)

[SO75]

890 West Pender Street, Suite 600
Vancouver, British Columbia
Canada V6C 1J9
778-998-5000
133 Hampshire Road
Wellesley, MA, 02481, USA
617-571-6006
www.imaginmedical.com

CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt & Stuttgart Symbol: DPD2
NR-2017-IME-07
NEWS RELEASE
Stock Options Granted
Vancouver, B.C. and Boston, MA, April 10, 2017 – Imagin Medical (CSE: IME) (OTC PINK:
IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today that
pursuant to the Company’s Stock Option Plan, an aggregate of 300,000 shares have been
granted to a consultant as incentive stock options at an exercise price of $0.12 per share.
The options are exercisable for a period of five years, ending on April 10, 2022.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the
use of endoscopes. The Company believes it will radically improve the way physicians detect
cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth
most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50%
recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced,
ultrasensitive imaging technology is based upon improved optical designs and advanced light
sensors. Learn more at www.imaginmedical.com.
ON BEHALF OF THE BOARD:
Jim Hutchens,
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: [phone]
Email: [e-mail]
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does